Squalane Is No Longer Just an Emollient: Can Sepilife NEOS Really Change ‘Clean Beauty’ Formulation?

Why this launch matters

Seppic announced Sepilife NEOS on 15 September 2026 as a patented liquid polymer associated with a squalane phase. For formulators, that positioning is notable because it moves squalane beyond its familiar consumer-facing role as an emollient and into the technical work of controlling texture, stability and flow.

This is a business-to-business formulation signal, not a consumer product recommendation. The useful question is not whether the ingredient sounds new, but which claimed advantages are documented, which depend on supplier testing and which still need independent or formulation-specific confirmation.

What the supplier actually claims

The launch material says the ingredient can support emulsions with up to 35% oil phase without an additional emulsifier or neutralization step, can be processed cold, and can span sprayable textures through richer creams. It also describes a quick-break, fresh and non-tacky sensory profile, plus compatibility with oils and alpha-hydroxy-acid formulations.

Seppic additionally reports 65% natural-origin content, describes the material as ethoxylate-free and uses a “non-microplastic” claim. These are supplier statements. They may be commercially relevant, but they are not equivalent to independently replicated performance, a life-cycle assessment or a regulator’s product-specific determination.

The data package readers still need

The public announcement does not provide the complete INCI declaration, recommended use range, patent number, polymer identity, residual-monomer or impurity limits, or the full method and sample size behind its tolerance statement. Those omissions prevent a robust comparison with established rheology modifiers.

It also does not publish full stability protocols, preservative-challenge results, packaging compatibility, competitor controls or statistically detailed sensory testing. A formulation team should request the technical data sheet, safety data, regulatory dossier and test reports before making performance or sustainability claims.

Natural-origin is a calculation, not a safety verdict

ISO 16128-2 provides approaches for calculating natural, natural-origin, organic and organic-origin indexes for cosmetic ingredients and products. The standard can therefore help explain how a percentage such as 65% was derived when the inputs and calculation are disclosed.

ISO also states important boundaries: it does not determine product claims or labeling, human safety, environmental safety, packaging or regulatory compliance. A natural-origin index should never be translated into “safer,” “greener” or “better tolerated” without separate evidence.

How to read the non-microplastic claim

EU Regulation 2023/2055 restricts synthetic polymer microparticles under REACH and contains detailed definitions, exclusions and transition provisions. Whether a particular polymer sits inside or outside that framework depends on technical characteristics, not on a marketing phrase alone.

LifeCareYou cannot independently confirm the “non-microplastic” positioning from the launch page. Verification would require the polymer identity and relevant particle, solubility, degradability or exemption documentation in the supplier’s technical dossier.

What existing squalane evidence can—and cannot—show

A 2023 Cosmetic Ingredient Review safety assessment re-evaluated squalane and squalene as cosmetic ingredients. That review is useful context for the free materials used in cosmetics, including available exposure and safety information.

It does not establish the safety of a new squalane-associated polymer, its manufacturing residuals, preservatives or every finished formula containing it. The CIR process is also industry funded, a limitation that should be visible when weighing the evidence.

Formulation and consumer-safety boundary

Cold processing may reduce some heating steps, but the announcement supplies no measured energy comparison or life-cycle assessment. Likewise, compatibility with an AHA-containing prototype does not mean every acid formula will remain stable, effective or well tolerated across pH, packaging and use conditions.

Finished products still need appropriate stability, microbiological protection, packaging compatibility and irritation or sensitization assessment. FDA guidance places responsibility on manufacturers to substantiate cosmetic ingredient and finished-product safety; this article is educational and is not medical advice.

LCY Evidence Meter and commercial disclosure

Evidence verdict: B for the existence and specifications of the launch; C for rheology, sensory and 35%-oil performance because the accessible evidence is supplier generated; C-minus for tolerance and “non-microplastic” positioning until the underlying dossier is available. Overall, this is a credible formulation trend worth watching, not a proven consumer superiority claim.

Commercial disclosure: LifeCareYou has no disclosed relationship with Seppic, did not receive payment or products for this article and does not sell Sepilife NEOS. No affiliate link is used. Editorial assessment remains separate from any future advertising or partnership activity.